![]() |
![]() |
Legal status
Patent in force
(51) | INT.CL. | A61K 39/395 | (2006.01) |
C07K 16/28 | (2006.01) |
(11) | Number of the document | 3283107 |
(13) | Kind of document | T |
(96) | European patent application number | 16718835.8 |
Date of filing the European patent application | 2016-04-15 | |
(97) | Date of publication of the European application | 2018-02-21 |
(45) | Date of publication and mention of the grant of the patent | 2020-05-27 |
(46) | Date of publication of the claims translation | 2020-09-10 |
(86) | Number | PCT/US2016/027913 |
Date | 2016-04-15 |
(87) | Number | WO 2016/168716 |
Date | 2016-10-20 |
(30) | Number | Date | Country code |
201562149325 P | 2015-04-17 | US | |
201562265268 P | 2015-12-09 | US | |
201562269000 P | 2015-12-17 | US | |
201662303855 P | 2016-03-04 | US |
(72) |
SADINENI, Vikram, US
QUAN, Yong, US
KASERER, Wallace, US
|
(73) |
Bristol-Myers Squibb Company,
Route 206 and Province Line Road, Princeton, NJ 08543,
US
|
(74) |
Jurga PETNIŪNAITĖ,
AAA Law, A. Goštauto g. 40B, Verslo centras "Dvyniai", LT-03163 Vilnius,
LT
|
(54) | Kompozicija apimanti ipilimumabo ir nivolumabo kombinaciją |
COMPOSITIONS COMPRISING A COMBINATION OF IPILIMUMAB AND NIVOLUMAB |
Payment date | Validity (years) | Amount | |
2025-03-05 | 10 | 231.00 EUR |
2026-04-15 |